Filing Flows › Health Care › Celularity (CELU)
Celularity (CELU) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Oct 20, 2026 · Celularity (CELU) Q2 2026 earnings results →
Q2 2026 Revenue down 5% year over year to $5.4M · 13¢ of every $1 of revenue kept as net profit · operating margin -78.0%
Celularity made $5.4M in Q2 2026 (-5% Y/Y): Product $4.1M, License Royalty and Other $719K, Service $652K. Operating margin -78.0%, net earnings $706K. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Oct 20, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $5.4M in Q2 2026, down 5% year over year and up 41% from the previous quarter. Product was the largest line at 75% of revenue. License Royalty and Other lost $1.4M year over year (down 65%), 448% of the total change.
Operating costs exceeded revenue by $4.2M, an operating margin of -78.0%. Total costs fell 55% while revenue fell 5%. Net earnings were $706K. The effective tax rate was 0.0%. Non-operating items added $4.9M, 700% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$1.1M. Non-cash charges added back $1.5M of depreciation and amortization and $844K of share-based compensation. Working capital and other items used $4.2M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Oct 20, 2026 | $5.4M | -5% | -78.0% | $706K | −$1.1M |
| Q1 2026 | 10-Q | Sep 29, 2026 | $3.8M | -66% | -263.5% | $874K | $1.4M |
| Q4 2025 | 10-K | Apr 30, 2026 | $4.1M | -77% | -537.5% | −$24.4M | −$5.1M |
| Q3 2025 | 10-Q | Nov 14, 2025 | $5.3M | -43% | -244.1% | −$23.1M | −$4.2M |
| Q2 2025 | 10-Q | Aug 29, 2025 | $5.7M | -53% | -276.6% | −$24.5M | −$999K |
| Q1 2025 | 10-Q | Aug 29, 2025 | $11.4M | -22% | -91.8% | −$19.8M | −$3.0M |
| Q4 2024 | 10-K | May 8, 2025 | $18.1M | +50% | -51.2% | −$13.3M | $1.6M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Celularity
We are a cellular and regenerative medicine company focused on advancing health longevity and redefining the standard of care for age-related disease using novel therapies derived from the post-partum human placenta. The objective of extending health longevity is to meaningfully reduce the duration and severity in which an individual experiences aging-related degenerative diseases and disorders associated with increased mortality towards the end of life. Aging is known to be a major risk factor for many degenerative disorders and diseases across multiple high-value therapeutic areas, including immunology and regenerative medicine. Common to all degenerative disorders and diseases is the progressive loss of function or structure (or both) of affected tissues and organs driven by underlying cellular dysfunction.
In its own words, from its 10-K, filed Apr 30, 2026.
Celularity against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -5% against the peers' median +7%. Operating margin: -78.0% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| CELU Celularity | Q2 2026 | $5.4M | -5% | -78.0% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Celularity 10-Q on SEC EDGAR · CIK 1752828 · Pharmaceutical Preparations
13F: who owns CELU and who is buying
More on CELU
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results